Myelofibrosis: Bone Marrow Scarring, Complications, and Management Options
Myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by clonal hematopoiesis, cytokine-driven marrow fibrosis, extramedullary hematopoiesis, and constitutional symptoms.
Pathophysiology
- Driver mutations: JAK2 V617F (60%), CALR (25%), MPL (5–10%), “triple-negative” (10%).
- Constitutive JAK-STAT signaling → megakaryocyte hyperplasia → TGF-β, PDGF release → fibroblast proliferation → collagen deposition (reticulin → collagen fibrosis).
- Extramedullary hematopoiesis → splenomegaly, hepatomegaly.
Clinical Manifestations
- Anemia (normocytic) – transfusion dependence in 30–40%.
- Splenomegaly (90%) – early satiety, LUQ pain.
- Constitutional: night sweats, weight loss, fever, pruritus.
- Thrombosis (arterial/venous) & bleeding (platelet dysfunction).
- Progression to AML (~10–20% at 10 yrs).
Prognostic Scoring
- IPSS / DIPSS-plus: Age, Hb, WBC, blasts, symptoms, karyotype, transfusion need, platelets.
- Risk groups: Low, Int-1, Int-2, High → median survival 1.5–11+ years.
Treatment
| Goal | Options |
|---|---|
| Symptom/spleen control | Ruxolitinib (JAK1/2 inhibitor) – FDA approved; fedratinib, pacritinib, momelotinib. |
| Anemia | Erythropoiesis-stimulating agents, danazol, immunomodulators (lenalidomide, pomalidomide), luspatercept (emerging). |
| Curative | Allogeneic HCT – only curative; age/comorbidity/fitness limit eligibility. |
| Supportive | Transfusions, hydroxyurea (cytoreduction), splenectomy (rare), radiation (symptomatic splenomegaly). |
